EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses

Panagiotis A Konstantinopoulos iD, Su-Chun Cheng, Elizabeth K Lee iD, Alexandre André B A da Costa iD, Doga Gulhan iD, Andrea E Wahner Hendrickson iD, Bose Kochupurakkal iD, David L Kolin iD, Elise C Kohn, Joyce F Liu iD, Richard T Penson iD, Elizabeth H Stover iD und 8 weitere

JCO Precision Oncology · 2024

DOI: 10.1200/po.23.00635 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift JCO Precision Oncology, 2024. Verfasst von Panagiotis A Konstantinopoulos und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. Hauptthemen laut MEDLINE: Gemcitabine, Ovarian Neoplasms, Isoxazoles, Pyrazines. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The multicenter, open-label, randomized phase 2 NCI-9944 study ( NCT02595892 ) demonstrated that addition of ATR inhibitor (ATRi) berzosertib to gemcitabine increased progression-free survival (PFS) compared to gemcitabine alone (hazard ratio [HR]=0.57, one-sided log-rank P = .044, which met the one-sided significance level of 0.1 used for sample size calculation). METHODS We report here the final overall survival (OS) analysis and biomarker correlations (ATM expression by immunohistochemistry, mutational signature 3 and a genomic biomarker of replication stress) along with post-hoc exploratory analyses to adjust for crossover from gemcitabine to gemcitabine/berzosertib. RESULTS At the data cutoff of January 27, 2023 (>30 months of additional follow-up from the primary analysis), median OS was 59.4 weeks with gemcitabine/berzosertib versus 43.0 weeks with gemcitabine alone (HR 0.79, 90% CI 0.52 to 1.2, one-sided log-rank P = .18). An OS benefit with addition of berzosertib to gemcitabine was suggested in patients stratified into the platinum-free interval ≤3 months (N = 26) subgroup (HR, 0.48, 90% CI 0.22 to 1.01, one-sided log-rank P =.04) and in patients with ATM-negative/low (N = 24) tumors (HR, 0.50, 90% CI 0.23 to 1.08, one-sided log-rank P = .06). CONCLUSION The results of this follow-up analysis continue to support the promise of combined gemcitabine/ATRi therapy in platinum resistant ovarian cancer, an active area of investigation with several ongoing clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GemcitabineOvarian NeoplasmsIsoxazolesPyrazinesHumansFemaleDeoxycytidineCarcinoma, Ovarian EpithelialProtein Kinase InhibitorsAtaxia Telangiectasia Mutated Proteins

Substanzen

GemcitabineberzosertibDeoxycytidineProtein Kinase InhibitorsATR protein, humanAtaxia Telangiectasia Mutated ProteinsIsoxazolesPyrazines

Autor:innen und Institutionen

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, MA.
  • Department of Biomedical Informatics and Ludwig Center at Harvard, Harvard Medical School, Boston, MA.
  • Department of Medical Oncology, Mayo Clinic, Rochester, MN.
  • Department of Pathology, Brigham and Women's Hospital, Boston, MA.

ORCID-Profile: Panagiotis A Konstantinopoulos, Elizabeth K Lee, Alexandre André B A da Costa, Doga Gulhan, Andrea E Wahner Hendrickson, Bose Kochupurakkal, David L Kolin, Joyce F Liu, Richard T Penson, Elizabeth H Stover, Madeline Polak, Alan D D'Andrea, Geoffrey I Shapiro, Ursula A Matulonis

Förderung

  • NCI NIH HHS

Zitieren

APA

Konstantinopoulos, P. A., Cheng, S. C., Lee, E. K., da Costa, A. A. B. A., Gulhan, D., Wahner Hendrickson, A. E., Kochupurakkal, B., Kolin, D. L., Kohn, E. C., Liu, J. F., Penson, R. T., Stover, E. H., Curtis, J., Sawyer, H., Polak, M., Chowdhury, D., D'Andrea, A. D., Färkkilä, A., Shapiro, G. I., & Matulonis, U. A. (2024). Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses. JCO Precision Oncology. https://doi.org/10.1200/po.23.00635

Vancouver

Konstantinopoulos PA, Cheng SC, Lee EK, da Costa AABA, Gulhan D, Wahner Hendrickson AE, et al. Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses. JCO Precision Oncology. 2024. doi:10.1200/po.23.00635

BibTeX
@article{Konstantinopoulos2024,
  author = {Konstantinopoulos, Panagiotis A and Cheng, Su-Chun and Lee, Elizabeth K and da Costa, Alexandre André B A and Gulhan, Doga and Wahner Hendrickson, Andrea E and Kochupurakkal, Bose and Kolin, David L and Kohn, Elise C and Liu, Joyce F and Penson, Richard T and Stover, Elizabeth H and Curtis, Jennifer and Sawyer, Hannah and Polak, Madeline and Chowdhury, Dipanjan and D'Andrea, Alan D and Färkkilä, Anniina and Shapiro, Geoffrey I and Matulonis, Ursula A},
  title = {Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses},
  journal = {JCO Precision Oncology},
  year = {2024},
  doi = {10.1200/po.23.00635}
}
Kostenlos starten →